BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Grant Life Sciences (GLIF.OB) And Diagnostic Technologies Ltd. Are Exploring An Expanded Partnership beyond Their Initially Proposed Association To Develop And Commercialize Grant's Cervical Cancer-Diagnostic Platform


10/30/2006 11:07:30 AM

LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’) Inc. (OTC BB: GLIF) announced today that it is exploring an expanded partnership with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant’s cervical cancer-diagnostic technology. The original proposed association between the two companies, assuming acceptable due diligence by DTL, was to have been a definitive Licensing Agreement that would include an upfront licensing fee of $250,000 paid to Grant. In addition, DTL would conduct all product development at its own cost, including clinical trials, associated with the commercialization of products developed from Grant’s cervical cancer-diagnostic technology. Upon commercialization, DTL would pay Grant an ongoing royalty on sales of the products developed, according to the definitive Licensing Agreement.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES